



# Anvisa- Brazil Regulatory Updates

Thiago Rezende P. Cunha  
Head of Medical Devices Inspection Office  
Brazilian Health Regulatory Agency - ANVISA





## Brazilian Health Regulatory Agency Brasília – Brazil









# Brazilian GMP Certificate

## Resolution RDC nº687/2022

- Compulsory for market authorization of medical devices Risk Class III and IV
- Valid for 2 years (general)
- Valid for 4 years (MDSAP)





**MINISTÉRIO DA SAÚDE**  
**AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA**

**CERTIFICADO DE BOAS PRÁTICAS DE FABRICAÇÃO E CONTROLE DE PRODUTOS PARA SAÚDE**

Considerando o disposto na Lei nº 9.782, de 26 de janeiro de 1999, o Decreto nº 3.029, de 16 de abril de 1999 e a publicação no Diário Oficial da União por meio da Resolução RE nº 1.843 na data de 29/05/2022 certifico que a empresa, a seguir descrita, cumpre com a legislação sanitária vigente, quanto às Boas Práticas de Fabricação de produtos para saúde exigidas pela autoridade sanitária brasileira, estando sujeita a inspeções periódicas.

Empresa: Labtest Diagnóstica S/A CNPJ: 16.516.296/0001-08

Endereço: Avenida Paulo Ferreira da Costa, nº 600, Distrito Industrial Vista Alegre, Lagoa Santa, Minas Gerais CEP: 33400-000

Autorização: 1000901 Expediente: 4873435/22-6

Certificado de Boas Práticas de Fabricação de Produtos para Saúde:

Produtos para diagnóstico de uso in vitro das classes III e IV.

Motivo: Publicado deferimento, subsidiado por critérios renovação automática


Validade até: 29/05/2025

Documento assinado eletronicamente por Marcus Aurelio Miranda de Araujo, Gerente-Geral de Inspeção e Fiscalização Sanitária, em 01/06/2023, às 14:55, conforme horário oficial de Brasília, com fundamento no § 3º do art. 4º do Decreto nº 10.543, de 13 de novembro de 2020 [http://www.planalto.gov.br/ccivil\\_03/\\_ato2019/2022/20220020/decreto/D10543.htm](http://www.planalto.gov.br/ccivil_03/_ato2019/2022/20220020/decreto/D10543.htm).



A autenticidade deste documento pode ser conferida no site <https://sei.anvisa.gov.br/autenticidade>, informando o código verificador 2408225 e o código CRC 84355209.











## Resolution RDC n° 982/2025

**Compliance monitoring of medical devices manufacturers based on risk.**

***“Artificial Intelligence may be used in the process, as long as it meets Anvisa's technical standards of consistency, data protection, traceability and technical validation.”***











# Criteria for risk classification

- Risk class of the products
- Complexity of the facility and activities
- Compliance history with GMP standards
- Marketing complaints
- Major Changes (if applicable)
- Time since last Anvisa inspection





# Manufacturers Classification

## High Risk Manufacturers

- Perform on-site inspection

## Medium Risk Manufacturers

- Technical review



## Low risk companies

- Certificate issue / Monitoring





# Use of MDSAP by Anvisa

## MDSAP reports for granting Anvisa initial GMP certifications

- The audit reports are reviewed by an Anvisa inspector
- Must cover all requirements from RDC 665/2022
- MDSAP Certificates used for Anvisa GMP Recertification



**MDSAP**  
Medical Device Single Audit Program





# Use of MDSAP by Anvisa

## Validity of GMP Certificate

**RDC 850/2024** – Validity of Anvisa GMP certificates issued through MDSAP extended from 2 to 4 years

Validity is conditioned upon the manufacturer's permanence in the program during the whole validity period of the certificate

Encourage manufacturers in joining MDSAP

| Year  | # GMP Certificates Issued<br>Based on MDSAP Reports (%<br>of total) |
|-------|---|
| 2017  | 38 (4.7%)   |
| 2018  | 107 (19.3%)   |
| 2019  | 374 (48.7%)   |
| 2020  | 544 (49.1%)   |
| 2021  | 529 (51.4%)   |
| 2022  | 621 (59.7%)   |
| 2023  | 659 (59.1%)   |
| 2024  | 708 (61.2%)   |
| *2025 | 637 (64.7%)   |

\*Until August 31<sup>st</sup>



<https://www.mdsap.global/>

[About](#) [Auditing Organizations](#) [Manufacturers](#) [Documents](#) [FAQs](#) [Training](#) [News](#) [Glossary](#) [Contact](#)

## Medical Device Single Audit Program

MDSAP allows a recognized Auditing Organization (AO) to conduct a single regulatory audit of a medical device manufacturer that satisfies the relevant requirements of participating Regulatory Authorities (RAs).




**What is MDSAP?**



**Benefits and Use**



**Performance**



# Eligibility of Medical Device Organizations (MDOs) to apply for MDSAP certification

---

**Code:** MDSAP AU P0038.001    **Version date:** 28 July 2025    **Effective date:** 1 August 2025

**Category:** [Audit procedures and forms](#)

The purpose of this procedure is to establish a voluntary pilot program allowing eligible Medical Device Organizations (MDOs) to voluntarily participate in and apply for MDSAP certification.

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please [contact us](#) for help.





# Unique Device Identification

## RDC 591/2021 and RDC 884/2024

- Final phase of development
- Launching (Q3-2025)
- Fully populated until 2031.





# Number of MD Market Authorizations per Year in Brazil

|                     |           | 2021        | 2022        | 2023        | 2024        |
|---------------------|-----------|-------------|-------------|-------------|-------------|
| <b>Notification</b> | Class I   | 3102        | 2718        | 2711        | 2797        |
|                     | Class II  | 3443        | 3751        | 4162        | 4205        |
| <b>Registration</b> | Class III | 938         | 1014        | 718         | 921         |
|                     | Class IV  | 254         | 328         | 300         | 393         |
| <b>Total</b>        |           | <b>7737</b> | <b>7811</b> | <b>7891</b> | <b>8320</b> |

Active Authorizations  
of Medical Devices

**91.707**

(31 dec 2024)



## Market Authorizations in Brazil

| Country           | Products |
|-------------------|----------|
| Brazil            | 31,3%    |
| China             | 18,0%    |
| USA               | 16,6%    |
| Germany           | 8,9%     |
| Italy             | 2,4%     |
| France            | 2,2%     |
| Korea             | 1,9%     |
| India             | 1,9%     |
| Rest of the world | 16,8%    |







# Reliance mechanisms for pre-market authorizations

## IN 290/2024 - effective since Jun / 2024

- Product registration certificates from Equivalent Foreign Regulatory Authorities used for market authorization in Brazil
- Initially from the official member authorities of MDSAP (AUS, CAN, JAP, USA)

| Reliance Data                | Results |
|------------------------------|---------|
| Requests                     | 382     |
| Concluded                    | 184     |
| Approved                     | 169     |
| Not approved                 | 15      |
| Percentage of total requests | 15,5%   |



# Conclusion

## Our values (2025/2026)

- Safety of the population
- Optimization of resources
- Reliance and regulatory convergence
- Transparency and Impartiality
- Use of innovation



**Thank you!**

**Obrigado!**

**ありがとう**



Thiago Rezende P. Cunha  
Head of Medical Devices Inspection Office  
Brazilian Health Regulatory Agency